ArticleAmerican journal of respiratory and critical care medicine2023
The Genetic Landscape of Familial Pulmonary Fibrosis.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.American journal of respiratory and critical care medicine · 2025Guideline
- Next-Generation Sequencing in Pulmonary Fibrosis: Translational Promise and Current Clinical Limitations.Current issues in molecular biology · 2026Review
- Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Efficacy and safety of danazol for pulmonary fibrosis or bone-marrow failure associated with telomere-related gene mutation.ERJ open research · 2026Article
- Age-dependent Genetic Risk in Pulmonary Fibrosis Patients and Relatives.medRxiv : the preprint server for health sciences · 2026Article
- The Endothelial Cell Perspective in Pulmonary Fibrosis: From Cell Fate Decisions, Intercellular Communication, and EndoMT to Emerging Therapies.Canadian respiratory journal · 2026Review
- Mechanical Cues Regulate Cargo Sorting and Export at the Golgi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Adult male patients withERJ open research · 2026Article
- Genetic Familial Interstitial Lung Disease.Clinics in chest medicine · 2025Review
- Non-coding genetic elements of lung cancer identified using whole genome sequencing in 13,722 Chinese.Nature communications · 2025Article
- Dominant Form ofAmerican journal of respiratory and critical care medicine · 2025Article
- Endothelial sensitivity to pro-fibrotic signals links systemic exposure to pulmonary fibrosis.Cell death & disease · 2025Article
- The Hypoxia-Retinoid Axis in Idiopathic Pulmonary Fibrosis: Multifaceted Etiology and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Accelerated biological ageing in familial pulmonary fibrosis.The European respiratory journal · 2025Article
- Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis.Nature genetics · 2025Article
- New perspectives on the progression of pulmonary fibrosis: the cascade from aberrant microvascular endothelial cell activation to fibrosis.Frontiers in medicine · 2025Review
- An Overview of the Role of Genetic factors in Idiopathic Pulmonary Fibrosis: Insights from Epidemiology to Prognosis.International journal of medical sciences · 2025Review
- GREGoR: Accelerating Genomics for Rare Diseases.ArXiv · 2024Article
- Progressive Early Interstitial Lung Abnormalities in Persons at Risk for Familial Pulmonary Fibrosis: A Prospective Cohort Study.American journal of respiratory and critical care medicine · 2024Article
- Cancer treatments as paradoxical catalysts of tumor awakening in the lung.Cancer metastasis reviews · 2024Review
Corrections and comments
- Commented on by
Authors and funding
26 authors at 10 institutions in 1 country.
Qi LiuDepartment of Biostatistics.
Yuan ZhouDepartment of Biostatistics.
Joy D CoganDivision of Medical Genetics and Genomic Medicine, Department of Pediatrics.
Daphne B MitchellDivision of Allergy, Pulmonary and Critical Care Medicine.
Quanhu ShengDepartment of Biostatistics.
Shilin ZhaoDepartment of Biostatistics.
Youhuang BaiDepartment of Biostatistics.
Kristen K CiomborDivision of Hematology and Oncology, and.
Carleen M SabusapDivision of Allergy, Pulmonary and Critical Care Medicine.
M Merced MalabananDivision of Allergy, Pulmonary and Critical Care Medicine.
Cheryl R MarkinDivision of Allergy, Pulmonary and Critical Care Medicine.
Katrina DouglasDivision of Allergy, Pulmonary and Critical Care Medicine.
Guixiao DingDivision of Allergy, Pulmonary and Critical Care Medicine.
Nicholas E BanovichTranslational Genomics Research Institute, Phoenix, Arizona.
Deborah A NickersonDepartment of Genome Sciences.
Elizabeth E BlueDepartment of Medicine, and.
Michael J BamshadDepartment of Genome Sciences.
Kevin K BrownNational Jewish Health, Denver, Colorado.
David A SchwartzDepartment of Medicine, School of Medicine, University of Colorado Denver, Denver, Colorado; and.
John A PhillipsDivision of Medical Genetics and Genomic Medicine, Department of Pediatrics.
Ruben Martinez-BarricarteDivision of Genetic Medicine, Department of Medicine, and.
Margaret L SalisburyDivision of Allergy, Pulmonary and Critical Care Medicine.ORCID 0000-0001-8217-6955
Yu ShyrDepartment of Biostatistics.
James E LoydDivision of Allergy, Pulmonary and Critical Care Medicine.
Jonathan A KropskiDivision of Allergy, Pulmonary and Critical Care Medicine.
Timothy S BlackwellDivision of Allergy, Pulmonary and Critical Care Medicine.ORCID 0000-0002-0337-7052
Pulmonary and Allergy Associates · USCancer Research And Biostatistics · USPediatrics and Genetics · USVanderbilt University · USBrotman Baty Institute · USNational Jewish Health · USPalmetto Hematology Oncology · USTranslational Genomics Research Institute · USUniversity of Colorado Denver · USUniversity of Washington · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MMechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SCHWARTZ, DAVID ALBERT · 2010 to 2020
$21.6MUW Center for Mendelian GenomicsU54HG006493 · NHGRI · UNIVERSITY OF WASHINGTON · PI BAMSHAD, MICHAEL JOSEPH, NICKERSON, DEBORAH A · 2012 to 2015
$20.0MUniversity of Washington Mendelian Genomics Research Center (UW-MGRC)U01HG011744 · NHGRI · UNIVERSITY OF WASHINGTON · PI MICHAEL Joseph BAMSHAD, Evan Eichler · 2021 to 2026
$15.8MUW Center for Mendelian GenomicsUM1HG006493 · NHGRI · UNIVERSITY OF WASHINGTON · PI BAMSHAD, MICHAEL JOSEPH, LEAL, SUZANNE M · 2016 to 2020
$15.3MTargeting early events in MUC5B-driven lung injury and fibrosisP01HL162607 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz · 2023 to 2026
$12.4MSpatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosisR01HL145372 · NHLBI · TRANSLATIONAL GENOMICS RESEARCH INST · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2019 to 2026
$6.0MPreclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3MMolecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5MGenes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0MMechanisms of epithelial repair and remodeling in pulmonary fibrosisR01HL153246 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2020 to 2024
$2.8MThromboxane Receptor Signaling in Pulmonary FibrosisR01HL151016 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2020 to 2023
$2.1MBLRD VA I01 BX002378BLRD VA I01 BX005295NCATS NIH HHS UL1 TR002243NHGRI NIH HHS U01 HG011744NHGRI NIH HHS U54 HG006493NHGRI NIH HHS UM1 HG006493NHLBI NIH HHS K23 HL141539NHLBI NIH HHS P01 HL092870NHLBI NIH HHS P01 HL162607NHLBI NIH HHS R01 HL145372NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL151016NHLBI NIH HHS R01 HL153246NHLBI NIH HHS R01 HL158668NHLBI NIH HHS UG3 HL151865NHLBI NIH HHS UH3 HL151865
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lung Diseases, InterstitialPulmonary FibrosisEndothelial CellsGenetic Predisposition to DiseaseHumansReceptors, Lysophosphatidic AcidRisk FactorsTelomereGPR87 protein, humanReceptors, Lysophosphatidic Acidgenetic rare variantsidiopathic pulmonary fibrosisinterstitial lung diseasetelomerasewhole exome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.